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Abstract
Background:  Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe
inherited cardiac disorder caused by mutations predominantly in the ryanodine receptor (RyR2)
gene. We sought to identify mutations in genes affecting cardiac calcium cycling in patients with
CPVT and in less typical familial exercise-related ventricular arrhythmias.
Methods and Results: We recruited 33 consecutive patients with frequent ventricular
premature complexes (VPCs) without structural heart disease and often history of syncope or
sudden death in family. Sixteen of the patients featured a phenotype typical of CPVT. In 17 patients,
VPCs emerged also at rest. Exercise stress test and echocardiography were performed to each
patient and 232 family members. Familial background was evident in 42% of cases (n = 14). We
sequenced all the coding exons of the RyR2, FKBP1B, ATP2A2 and SLC8A1 genes from the index
patients. Single channel recordings of a mutant RyR2 were performed in planar lipid bilayers. Two
novel RyR2 missense mutations (R1051P and S616L) and two RyR2 exon 3 deletions were identified,
explaining 25% of the CPVT phenotypes. A rare variant (N3308S) with open probabilities similar
to the wild type channels in vitro, was evident in a patient with resting VPCs. No disease-causing
variants were detectable in the FKBP1B, ATP2A2 or SLC8A1 genes.
Conclusion: We report two novel CPVT-causing RyR2 mutations and a novel RyR2 variant of
uncertain clinical significance in a patient with abundant resting VPCs. Our data also strengthen the
previous assumption that exon 3 deletions of RyR2 should screened for in CPVT and related
phenotypes.
Background
Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is a severe, autosomal dominantly inherited disor-
der characterized by stress-induced polymorphic ventricu-
lar tachycardias in a structurally normal heart [1-3]. Thus
far, the ryanodine receptor type 2 (RyR2) and calseques-
trin (CASQ2) genes have been identified to underlie the
disease. Yet, many patients with clinical features compara-
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ble with CPVT harbor no apparent mutations in these
genes, thus reflecting the existence of yet unidentified
non-coding mutations or genetic heterogeneity of this dis-
order.
Mutations or variants in calstabin (FKBP1B), sarcoplasmic
reticulum Ca2+-ATPase (ATP2A2) or sodium-calcium
exchanger (SLC8A1) genes have until now not been
reported to be associated with increased risk of human
ventricular tachyarrhythmias. Although still a matter of
controversy [4], a number of delicate in vitro studies sug-
gest that depletion of calstabin, which normally stabilizes
the RyR2 channel complex, is related to CPVT pathogene-
sis [3,5,6]. SERCA2a (Ca2+-ATPase), an ion pump located
on the sarcoplasmic reticulum (SR) in a cardiac myocyte,
plays a pivotal role in transporting intracellular Ca2+ ions
back to the SR in the beginning of diastole. Thus far,
SERCA2a encoded by the ATP2A2 gene has been the target
of extensive in vitro and in vivo experiments in heart failure
only [7-10], whereas a mutated cardiac sodium-calcium
exchanger 1 (NCX1), the major Ca2+ ion remover in car-
diac myocyte, has been shown to cause cardiac fibrillation
in embryonic zebrafish hearts [11,12].
According to several investigators, circulating catecho-
lamines cause the abnormal activation of RyR2 channels
and thus an arrhythmogenic leak of Ca2+ ions from the
sarcoplasmic reticulum [13]. However, it has been
hypothesized that RyR2 mutations could lead to channel
dysfunction also in the absence of sympathetic stimuli
[14]. In this study, we aimed to broaden the knowledge of
disease-causing RyR2 mutations in resting and exercise-
induced VPCs and to elucidate the involvement of not
only RyR2, but also three other candidate genes in the
pathology of ventricular tachyarrhythmias. We hypothe-
sized that FKBP12.6, SERCA2a and NCX1, as integral pro-
teins in cardiac Ca2+ signaling, might play a role in the
pathogenesis of human ventricular arrhythmias and
which defects might manifest with clinical features resem-
bling CPVT.
Methods
Patients and controls
We recruited 33 consecutive symptomatic patients
referred to Helsinki University Hospital for genetic studies
of cardiac ion channel disorders because of frequent ven-
tricular premature complexes (VPCs) occurring during
exercise and consecutive VPCs, history of syncope and/or
sudden juvenile death in family. None had apparent
structural heart disease or prolonged QT interval. A total
of 16 patient featured arrhythmias typical of CPVT in the
exercise stress test. The remaining 17 subjects had fre-
quent VPCs and often salvos of VPCs also at rest, thus dif-
fering from CPVT phenotype. A health enquiry, a 12-lead
resting ECG, an exercise stress test, a cardiac ultrasonogra-
phy and 24-hour ambulatory ECG recording were regis-
tered from each index patient. If over ten VPCs were
evident in the exercise stress test of patient's first degree
relatives, the clinical examinations including 12-lead rest-
ing ECG, exercise stress test and cardiac ultrasonography
were extended to available second-degree relatives. A total
of 232 relatives were clinically evaluated in the course of
the study. History regarding the age of onset, episodes of
syncopal spells and occurrence of sudden juvenile (≤ 40
years) death in the patient's first and second degree rela-
tives were collected. The control DNA samples of 300
apparently healthy blood donors were provided by the
Finnish Red Cross Blood Service. An informed consent
was obtained from each patient and the Ethics Committee
of the department approved the study.
DNA analyses
We sequenced all the 105 coding exons and exon-intron
boundaries of RyR2 (NM_001035) gene using ABI 3730
Automatic DNA sequencer (Applied Biosystems, Foster
City, MA, USA) provided by the National Public Health
Institute of Finland. Reference sequences were obtained
from the National Centre for Biotechnology Information
(NCBI) database. The primer sequences, designed mainly
by N. Tiso, and reaction conditions for PCR amplification
are available by contacting the corresponding author. The
previously reported 1.1 kb RyR2  exon 3 deletion was
investigated using multiplex ligation-dependent probe
amplification (MLPA) analysis of RyR2  exon 3 (Salsa
MLPA Kit P168, MRC Holland, Amsterdam, the Nether-
lands) and with PCR using primers CACAGAACAGGAC-
CAAGTTAGAGG (forward) in intron 2 and
CATTACCTTCCTGACACACTTCAT (reverse) in intron 3
of the RyR2 gene [15]. When present, the architecture of
the deletion was investigated in more detail by DNA
sequencing. A functional candidate gene approach was
applied to probands that failed to present RyR2 muta-
tions. These indexes were additionally screened for varia-
tions in the exonic regions of FKBP1B  (NM_004116),
ATP2A2 (NM_170665) and SLC8A1 (NM_021097) genes
coding for the integral proteins in cardiac Ca2+ signaling.
CPVT caused by mutations in the CASQ2 gene is proposed
to follow the autosomal recessive inheritance, while the
disease phenotype in our patients with a familial disorder,
followed autosomal dominant pattern. In addition,
sequencing of the CASQ2 gene was excluded from the
study protocol because our previous study on CASQ2
failed to detect any rare variants in Finnish CPVT patients
[16]. Primer sequences and the conditions for sequencing
the three genes are obtainable by contacting the authors.
Detection of observed allelic RyR2  variants in family
members and 300 healthy controls was achieved by dena-
turing High Performance Liquid Chromatography
(dHPLC, WAVE Nucleic Acid Fragment Analysis System
HSM 3500A). Direct sequencing confirmed the genomicBMC Medical Genetics 2009, 10:12 http://www.biomedcentral.com/1471-2350/10/12
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variations leading to divergent chromatogram profiles.
The detection of ATP2A2 T982M in the relatives and con-
trols was achieved by restriction analysis utilizing the Lwel
enzyme (Fermentas International Inc, Burlington,
Ontario, Canada).
In vitro electrophysiological studies
RyR2 N3308S mutagenesis was performed with Quik-
Change II XL mutagenesis kit (Stratagene, La Jolla, CA,
USA) using cassettes of hRyR2 subcloned into pBlueScript
vector. Mutated fragments of hRyR2 were cloned back
into full-length pCMV5/hRyR2 with FseI and NheI.
HEK293 cells were co-transfected with 10 μg of pCMV5/
hRyR2 and an equal molar amount of pCMV5/FKBP12.6
per T175 flask using calcium phosphate precipitation
technique.
Single channel recordings were conducted in planar lipid
bilayers under voltage clamp conditions. Microsomes
containing the recombinant RyR2 channels were added to
the cis-chamber and fused to the lipid bilayer consisting of
3:1 phosphatidyl ethanolamine/phosphatidyl serine
(Avanti Polar Lipids, Alabaster, AL, USA). Fusion was
induced by adding KCl to the cis-chamber, and the created
ion gradient was eliminated after fusion by perfusing the
chamber with cis-solution. The bathing solutions were as
follows: cis solution, 50 mM KCl, 250 mM HEPES, 125
mM TRIS, 1 mM EGTA, 0.5 mM CaCl2; trans-solution 50
mM KCl, 53 mM Ba(OH)2 and 250 mM HEPES. All exper-
iments were carried out in pH 7.35, and free Ca2+ concen-
tration was determined using the program CHELATOR.
20 mM CaCl2 was added sequentially to the cis-side, and
the channel activity was recorded for at least 3 min in each
concentrations. At the end of each experiment, ryanodine
was applied to confirm the class of the channel. Data were
collected using AxoScope1 (Axon Instruments, Foster
City, CA, USA) and analyzed by pClamp 6 program (Axon
Instruments). The open probability (P0) was identified by
50% threshold analysis.
Statistical analyses
Statistical analysis was performed with student's t-test for
continuous variables and with X2 and Fischer's exact test
for dichotomous variables using the SPSS 13.0 software.
P-value of < 0.05 was considered statistically significant.
Results
Clinical studies
VPCs appeared in 16 cases solely upon physical exercise
but not in resting conditions thus resembling the arrhyth-
mias of classical catecholaminergic polymorphic ventricu-
lar tachycardia (Group A) [1,17,18]. In seventeen of the
33 patients, frequent VPCs were also observed at rest and
at the recovery phase of the exercise stress test (Group B)
as illustrated by an exemplary ECG recording (Figure 1)
and by bar graphs summarizing the number of VPCs per
hour in the 24 h Holter recordings (Figure 2). The clinical
data from the subjects are summarized in Table 1. In the
two groups, the mean age of onset was 26 ± 17 years. In
the exercise stress tests, the number of successive VPCs was
greater in the CPVT phenotype, but the difference was not
statistically significant between the two groups (p = 0.08).
The probands in the group B had statistically significantly
more VPCs (p < 0.001) and more consecutive ventricular
complexes (p < 0.01) than the CPVT patients in the 24 h
ECG recordings. A total of six probands (38%) in the
group A had relatives featuring similar arrhythmias in the
clinical evaluation, whereas in the group B, seven
probands (41%) had affected relatives. In group A, there
were more syncopal spells and sudden juvenile deaths in
Table 1: Clinical Characteristics of the Affected Individuals
CPVT (Group A) Resting VPCs (Group B) P
n 16 17 NS
Females, n (%) 6 (38) 13 (77) <0.05
Age at onset, y 25 ± 16 (10–64) 27 ± 18 (5–51) NS
Syncope, n (%) 14 (88) 9 (53) NS
Heart rate, bpm 60 ± 15 (38–98) 73 ± 20 (42–99) NS
QT, ms 430 ± 55 (350–550) 405 ± 55 (320–490) NS
QTc, ms 420 ± 25 (380–440) 430 ± 30 (380–450) NS
Exercise stress test Threshold heart rate, bmp 127 ± 30 (87–184) - -
Consecutive VPCs, n 4 ± 6 (0–15) 1 ± 1 (0–5) NS
24 hour ECG recording VPCs, n 560 ± 800 (0–2670) 13800 ± 11100 (224 – 33200) <0.001
Consecutive VPCs, n 1 ± 1 (0–3) 5 ± 6 (0–24) <0.01
Familial occurrence, n (%) 6 (38) 7 (41) NS
Affected relatives, n (%) 12 (16) 26 (17) NS
SD in family, n (%) 5 (31) 3 (18) NS
Values are mean ± SD (range). VPCs, ventricular premature complexes; ECG, electrocardiogram; SD, history of sudden death at age ≤ 40 in the 
first or second degree relatives; NS, Statistically non-significant.BMC Medical Genetics 2009, 10:12 http://www.biomedcentral.com/1471-2350/10/12
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the first and second-degree relatives, but the difference to
group B was not statistically significant. In both pheno-
types, one index patient had suffered from juvenile (≤ 40
years) sudden cardiac death.
Molecular genetic studies
Identification of RyR2 missense mutations
Direct DNA sequencing of the 105 coding exons of RyR2
gene revealed two novel missense mutations (R1051P and
S616L) in the group A [see Additional file 1]. The muta-
tions were located in evolutionarily conserved amino
acids [see Additional file 1] and could not be detected in
any of the 300 blood donors. The index patient carrying
RyR2 R1051P mutation (Figure 3A) was 35 years old and
had experienced several syncopal spells since the age of
30. Lateral ST-alterations typical of left ventricular hyper-
trophy emerged in resting ECG, but the echocardiography
revealed only a minor septal thickening up to 13 mm. The
son of the patient carrying the RyR2 R1051P mutation had
a similar phenotype, but the onset was at the early adoles-
cence and the exercise stress test performed thereafter
showed exercise-provoked VPCs characteristic for CPVT.
Furthermore, no morphological alterations could be
observed in the resting ECG or in the echocardiography. A
son of the index's cousin (A:IV:16 in Figure 3A), aged 19
years, received a diagnosis of hypertrophic cardiomyopa-
thy with septal thickening up to 20 mm and a 20 mmHg
– gradient in the outflow tract. No cardiac arrhythmias
were evident, and the patient lacked the R1051P muta-
tion. The rest of the family (n = 17) featured no abnormal-
ities in the clinical evaluation and did not carry the
familial RyR2 defect.
The S616L mutation (Figure 3B) occurred in a female ado-
lescent with exercise-induced syncopal spells since the age
of twelve. Resting ECG showed a partly ectopic rhythm,
Sample ECG recordings from the exercise stress tests in the Group A and B Figure 1
Sample ECG recordings from the exercise stress tests in the Group A and B. A 33-year-old male patient from 
Group A reported exercise-induced syncope since the age of 14. Resting ECG was normal except for a relative bradycardia of 
45 bpm (1). After the threshold heart rate of 128 bpm, the exercise stress test revealed polymorphic VPCs typical of CPVT (2) 
that disappeared in the recovery phase (3). Three of the 16 examined individuals in the family had a similar phenotype and car-
ried the RyR2 exon 3 deletion. The 57-year-old female patient in Group B showed frequent VPCs in baseline ECG (4), in the 
exercise stress test (5) and in the recovery phase (6). A total of 13 patients of the 77 clinically evaluated subjects in the family 
featured a similar atypical phenotype. No disease-causing variants were detectable in the screened genes.
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Sample 24-hour ambulatory ECG recordings in the Group A and B Figure 2
Sample 24-hour ambulatory ECG recordings in the Group A and B. The 24-hour ECG recording revealed a number 
of exercise-provoked VPCs (n = 51) occurring solely above the heart rate of 90 bpm in a typical CPVT patient from group A. 
In a patient from group B, VPCs (n = 8 042) occurred also in resting conditions. The number of VPCs per hour is indicated by 
gray bars. The maximal heart rate per hour is shown by the curves. ECG = electrocardiogram, VPC = ventricular premature 
complex, bpm = beats per minute.
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and exercise stress test revealed polymorphic VPCs in a
series of several beats. The mutation appeared to arise de
novo as the parents of the index featured no pathological
alterations in their exercise stress tests nor carried the RyR2
S616L.
In the group B, a novel RyR2 variation N3308S was dis-
covered, but it was also detectable in one of the 600 con-
trol alleles (Figure 3C). The proband was a 34-year-old
woman first presenting with palpitations and presyncopal
episodes due to right ventricular outflow tract arrhyth-
mias. Holter recordings uncovered over 20,000 predomi-
nantly single VPCs, but also bigeminial cycles and salvos
up to four successive beats. The coronary angiography
showed normal coronary arteries. The father of the index
patient carried the variant but was not available for clini-
cal evaluation. Two of the three descendants reported epi-
sodes of syncope and carried the same variant, yet their
exercise stress tests with less than ten single monomorphic
VPCs were judged to be within normal range.
Identification of RyR2 exon 3 deletions
An exon 3 deletion, approximately 1.1 kb in size, was
identified in two (13%) separate CPVT families. In Family
D (Figure 3), the 33-year old index patient featured synco-
pal spells and frequent bidirectional VPCs during exercise
at the time of diagnosis. His son, sister and niece featured
a similar symptomatic CPVT phenotype. During follow-
up of over 25 years, the index patient's son and sister
showed paroxysmal atrial fibrillation. The sister also fea-
tured sinusbradycardia and atrioventricular conduction
abnormalities, whereas only bradycardia was observed in
her affected daughter. Apart from the ascending aorta dil-
atation (up to 57 mm) in the index patient's sister, none
The pedigrees of the families carrying RyR2 R1051P (A), RyR2 S616L (B), RyR2 N3308S (C) and the RyR2 exon 3 deletions (D,E) Figure 3
The pedigrees of the families carrying RyR2 R1051P (A), RyR2 S616L (B), RyR2 N3308S (C) and the RyR2 exon 
3 deletions (D,E). The carrier status of the mutation is illustrated by black circles and squares. Clinically evaluated family 
members are shown with an asterisk. Open large squares present clinically affected individuals with CPVT phenotype, while 
open large circle symbolizes the disease phenotype of frequent VPCs also in resting conditions. Deceased individuals are indi-
cated with a slash.
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of the affected subjects showed major structural cardiovas-
cular abnormalities. The analyses of the available DNAs
revealed a 1.1 kb deletion of the RyR2  gene (c.168-
301_c.273+722del1128) eliminating the highly con-
served exon 3.
In the Family E (Figure 3), the index patient aged 39 years
featured presyncopal spells, atrial fibrillation, bradycardia
and multifocal VPCs up to runs of ventricular tachycardia
upon exercise stress test. In the follow-up, he showed
increased trabeculation of the left ventricle suggestive of
non-compaction cardiomyopathy. His son featured poly-
morphic VPCs upon exercise in the absence of atrial fibril-
lation. A molecular analysis of the RyR2 exon 3 deletion
revealed the previously reported [15] 1.1 kb base deletion
(c.168-228_c.273+793del1126) in these two patients of
Family E. Both types (Family D, Family E) of genomic
RyR2 deletions, although slightly different in their nature,
are predicted to result in an identical in-frame deletion of
35 amino acids (p.Asn57-Gly91) from the RyR2 protein.
Other genes affecting cardiac calcium signaling
Screening for mutations in FKBP1B and SLC8A1 genes did
not reveal any amino-acid alterations. A novel, conserved
polymorphism T982M in the ATP2A2 gene was detectable
in four (12%) individuals, two in both subgroups, and it
was also identifiable in 10 of the 291 (3%) control indi-
viduals (p = 0.07).
In vitro electrophysiological studies
Since the RyR2 N3308S mutation was associated with an
atypical clinical phenotype, it was considered pertinent to
study it in more detail in vitro. The representative data
from the single channel recordings of the wild type RyR2
and N3308S are shown in Figure 4. The wild type RyR2 (n
= 8) featured a mean open probability (Po) of 0.1 ± 0.1%
at 350 nM cytosolic Ca2+ concentration, 2.6 ± 1.9% at 700
nM and 10.6 ± 6.4% at upper systolic 1 μM cytosolic Ca2+
concentration (A). The measurements of RyR2 N3308S (n
= 8) showed a mean Po of 0.7 ± 0.3% at 350 nM, 2.9 ±
2.4% at 700 nM and 14.8 ± 6.9% at 1 μM cytosolic Ca2+
concentration (B). The open probabilities of the mutant
channel did not differ statistically significantly from the
wild type over the range of 90 nM free-[Ca2+]cis to maximal
activity. In addition, the kinetics, mean open time (To)
and mean closed time (Tc) of the channels were analo-
gous.
Discussion and conclusion
Despite marked progress in understanding the pathogen-
esis of inherited ventricular arrhythmias, the molecular
genetics of CPVT and frequent ventricular premature com-
plexes without structural heart disease is incompletely
known. In the present study, two CPVT families carried a
corresponding in-frame RyR2  exon 3 deletion that has
recently been characterized by Bhuiyan et al in two kin-
dred of exercise-related ventricular arrhytmias, atrial
arrhythmias, conduction defects and left ventricular dys-
function [15]. Previously, it was shown that the genomic
deletion of the RyR2 exon 3 occurred as a result of a Alu-
repeat mediated polymerase slippage during chromo-
somal replication [15]. Neither of the families in the
present study featured consistent structural abnormalities
suggesting that the deleted RyR2 exon 3 may underlie a
spectrum of a purely electric CPVT disorder to a more
complex disorders as shown previously [15]. Characteri-
The representative traces of single channel recordings of the RyR2 WT (A) and the RyR2 N3308S (B) at cytosolic Ca2+ concen- trations of 350 nM, 700 nM and 1 μM Figure 4
The representative traces of single channel recordings of the RyR2 WT (A) and the RyR2 N3308S (B) at 
cytosolic Ca2+ concentrations of 350 nM, 700 nM and 1 μM. The channel openings are upward deflections. The open 
probabilities (Po) of the recorded channels are shown in the bar graph (C). No statistically significant differences were observ-
able in the sensitivity of the channels to the cytosolic Ca2+ concentrations. Po = open probability, To = mean open time, Tc = 
mean closing time, c = closed state.
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zation of the large RyR2 exon 3 deletion independently in
altogether four unrelated families with CPVT-related dis-
orders thus far suggests that this region may be of notable
importance in the pathogenesis of inherited arrhythmia
disorders.
In the present study, four (25%) out of the 16 probands
featuring typical CPVT carried a disrupted RyR2 gene. In
our previous studies, a RyR2 defect has been evident in an
average of 40% of CPVT patients [18,16] similarly to other
patient populations [13]. As we sequenced the 105 exons
of the RyR2 gene and analyzed the DNAs for exon 3 dele-
tions, our study suggests existence of non-coding intron
mutations, other large yet unidentified genomic dele-
tions, alterations in the regulatory units or genetic hetero-
geneity of the disorder. Combining present data to our
previous studies, RyR2  alterations explain 35% of the
CPVT phenotype in the Finnish probands (n = 26) of
which 2 out of 9 (22%) appeared to be de novo mutations.
The low frequency of de novo mutations calls for system-
atic cardiovascular examinations for all first degree rela-
tives. In addition, the identified RyR2 S616L and R1051P
missense mutations are expected to extend the N-terminal
hot-spot region of the RyR2 gene which further challenges
the method of targeted mutational analysis in which only
previously mutation positive exons are sequenced.
Molecular genetic approaches should be applied in gain-
ing further understanding in familial VPCs that occur also
in resting conditions. Recently, several in vitro studies have
questioned the occurrence of arrhythmias in CPVT merely
in the presence of adrenergic stimulus [14,19]. In our
study, only one index showing resting VPCs carried a var-
iant in the RyR2 gene. According to the proposed criteria
for high risk right ventricular outflow tract – arrhythmias
[20], this phenotype with extremely frequent VPCs and a
history of syncope was of malignant nature. However, the
asparagine substitution to serine at position 3308 main-
tains the polarity of the amino acid and results in a neutral
replacement. In addition, the N3308S was detected in one
of the 300 apparently healthy controls. The single channel
experiments carried out in planar lipid bilayers did not
show enhanced sensitivity of the mutant channel to the
cytosolic Ca2+ under basal conditions. Collectively, the
evidence of the causal role of this variant is unconvincing
and suggests that the RyR2 N3308S is an innocent variant
despite its rare occurrence in the Finnish population.
However, a search for the variant in patients with a similar
phenotype may be justifiable in other populations.
Despite the lack of convincing disease-causing RyR2 muta-
tions in our patients with VPCs at rest, the occurrence of
syncopal spells and the proportion of familial occurrence
(38% vs. 41%) did not differ between the CPVT and rest-
ing VPC phenotype. Furthermore, the similar incidence of
sudden juvenile death among the first and second degree
relatives of the two groups suggests that even this pheno-
type with resting VPCs may be malignant. Elucidating the
genetic background in this heterogeneous group is funda-
mental so that the malignant forms of the disorder could
be identified. In the present study, the limited sample size
precludes any definitive statements of the occurrence of
rare mutations in these candidate genes in other study
populations. In addition, the lack of information concern-
ing the in vitro functional properties of the mutant RyR2
S616L and R1051P channels remains as a limitation of
the present study. We conclude that mutations in FKBP1B,
ATP2A2 and SLC8A1 appear subsidiary in the pathogene-
sis of frequent VPCs of unknown etiology in Finnish
patients. RyR2 involvement in potentially malignant fre-
quent resting VPCs requires further clarification. Large
genomic RyR2 deletions involving exon 3 provide a target
for future genetic studies in disorders resembling CPVT.
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